Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus valsartan in heart failure with preserved ejection fraction
NL-OMON47866Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing LCZ696 with valsartan (2 arms). Primary endpoint: Cumulative number of primary composite events. Started Dec 2014; status: active, not recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON47866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47866.